Feinstein Institutes receives $2.9M NIH grant for IVF genetic risk factors studies

·3 min read

The new funding will launch a series of studies exploring polygenic embryo selection, a new technology that may be used to screen embryos as part of IVF

MANHASSET, N.Y., August 02, 2021--(BUSINESS WIRE)--Genetic testing and selection of embryos generated from in vitro fertilization (IVF) have given rise to the controversial "designer baby" debate. Recently, the use of a new technology called polygenic embryo selection (PES) has developed to identify the risk for complex diseases of adulthood. To further study the accuracy – and the ethics – of PES, researchers at The Feinstein Institutes for Medical Research have been awarded a $2.9 million grant from the National Institutes of Health's (NIH) National Human Genome Research Institute (NHGRI).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210802005445/en/

Todd Lencz, PhD, professor in the Feinstein Institutes’ Institute of Behavioral Science and co-principal investigator on the new PES studies. (Credit: The Feinstein Institutes for Medical Research)

For decades, reproductive geneticists have been able to identify rare, serious genetic disorders like Down syndrome or cystic fibrosis prior to implantation of embryos in women undergoing IVF. But through PES, geneticists aim to evaluate embryos for more common diseases that may (or may not) emerge later in life, such as diabetes, schizophrenia or cancer. The four-year grant is led by the Feinstein Institutes’ Todd Lencz, PhD, in collaboration with Shai Carmi, PhD, of Hebrew University of Jerusalem and Gabriel Lázaro-Muñoz, PhD, of Baylor College of Medicine.

The research will address two aspects of PES and IVF. The first will include the use of statistical genetics to understand the possibilities and limitations of PES better. PES relies upon an examination of genetic differences scattered across the genome, each contributing a tiny amount of risk for a given disease; the total risk is measured by a polygenic risk score. The accuracy of a polygenic risk score in the context of PES is not well understood, but is critical to determining if and how PES can work.

Second, researchers will conduct interviews and surveys with doctors who perform IVF, prospective parents undergoing IVF, and others to gain insight into the attitudes, opinions, interests, and concerns around PES.

"The use of polygenic embryo selection has been proposed as one tool to reduce the burden of disease in future generations," said Dr. Lencz, professor in the Feinstein Institutes’ Institute of Behavioral Science and co-principal investigator of these new studies. "With support from the NIH we will be able to explore the ethical and scientific concerns and better understand the limitations PES may have."

Some companies offer PES screening even though the utility and effectiveness of this technique are without a solid scientific foundation. In the United States, PES is entirely unregulated. The ethical implications have not yet received consideration from doctors, patients or society as a whole and raised the debate of eugenics and designer babies. To date, there has been almost no research published to indicate the potential success of polygenic embryo selection.

"The human genome holds great promise to identify complex and serious diseases," said Ping Wang, MD, chief scientific officer of the Feinstein Institutes. "With the support of the NIH, Dr. Lencz will be able to add valuable and much-needed insight and scientific data concerning genetic embryo screening."

About the Feinstein Institutes

The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210802005445/en/

Contacts

Matthew Libassi
631-793-5325
mlibassi@northwell.edu

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting